齊翔騰達(002408.SZ)擬投資擴建順酐項目
格隆匯3月9日丨齊翔騰達(002408.SZ)公佈,公司於2012年12月20日召開的第二屆董事會第十五次會議審議通過了《關於投資建設年產10萬噸順丁烯二酸酐項目的議案》。
10萬噸/年順丁烯二酸酐(以下簡稱“順酐”)項目於2013年11月建成投產後,公司分別於2015年和2017年對順酐裝置進行擴建,截止目前公司順酐裝置的產能已達到20萬噸/年,為世界產能最大的順酐裝置。該裝置自投產以來,運行穩定,盈利狀況良好。
公司擬投資擴建的20萬噸/年順酐項目,是在原有20萬噸/年順酐裝置的基礎上進行的擴建,生產工藝成熟,生產經驗豐富。目前順酐下游市場前景廣闊,主要用於生產不飽和聚酯樹脂、富馬酸、潤滑油添加劑、農用化學品、塗料、耐熱苯乙烯樹脂等近百種下遊有機中間體和專用化學品,同時還可應用於可降解塑料PBS和PBAT等產品的生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.